Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > BNN Market Call

<< Previous

Bullboard Posts

Next >>

Comment by porksnifferon Sep 08, 2021 1:34pm

87 Views

Post# 33825396

RE:BNN Market Call

EbbFlow88 wrote: BNN Market Call - GUD

Someone called in on market call asking about GUD. Everytime I see knight come out in the public domain it seems no one is truly up to date with the GUD story. This investment manager is still talking about raising cash and no growth or earnings which is just not the case. I agree on it's still a show me story but it's still flying under the radar.

Actually the analyst was bang on. This turd has dropped 50% from highs set 4 years ago. The market is well aware of this trap and is not only staying away but churning shareholders for over a year now.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market